UPDATE: Stifel Nicolaus Raises PT to $9 on Boston Scientific Corporation Post Analyst Day

Stifel Nicolaus maintained Boston Scientific Corporation

with a Buy rating and raised the price target from $8.00 to $9.00. Stifel Nicolaus noted, "We left yesterday's Boston Scientific New York Analyst Day believing our basic thesis on BSX shares is unchanged. If anything, we left with increased conviction that after three years of negative top-line growth, BSX now has in place multiple avenues to re-accelerate sales growth back to mid-single digits by the 2016-2017 time frame. … Also evident throughout the meeting was the strong management team now in place at BSX and their clear and energetic strategic vision for the company. Overall, management laid out what we thought was a well thought-out and realistic plan to improve the growth and profitability prospects of the company." Boston Scientific Corporation closed at $7.59 on Tuesday.